Navigation Links
IDM Pharma Announces Phase 2 Follow-Up Data Showing IDM-2101 is Well Tolerated With Positive Survival Trend in Non-Small Cell Lung Cancer Patients
Date:6/2/2008

mparable group -- 60 percent versus 49 percent.

-- Median survival (IDM-2101 versus comparator group) -- 17.3 months

versus 12.0 months.

-- Stable disease >/= 3 months -- 54 patients (86%) treated with

IDM-2101.

-- Tumor Response IDM-2101 -- One patient had complete response; one

patient had partial response.

-- 17 patients (27%) treated with IDM-2101 continued treatment for one

year with no evidence of progressive disease

-- 14 patients (22%) treated with IDM-2101 continued treatment for two

years with no evidence of progressive disease

-- Measurable immune response - 91 percent of patients treated with

IDM-2101, who were tested for immune response, had a measurable

response to at least one of the epitopes included in the vaccine

with 64 percent responding to at least three of the epitopes.

-- Toxicities attributable to the vaccine were mild and consisted

primarily of injection site reactions.

"These results further support the survival trend and safety of IDM-2101 and will serve as a basis in determining an appropriate clinical pathway for this important treatment," said Timothy P. Walbert, president and chief executive officer, IDM Pharma, Inc.

About IDM-2101

IDM-2101 includes nine CTL epitopes from four tumor associated antigens (TAA) including two proprietary native epitopes and seven modified, or analog, epitopes and one universal epitope a source of T-cell help. Tolerance to TAA, which is a failure of the immune system to recognize the cancer as diseased tissue, is broken by using these analog epitopes which enhance the potency of the T cell response. The Phase 2 IDM-2101 study has been ongoing since late 2004 and patient treatment has been completed. Long-term follow-up is ongoing for overall survival.

About Lung Cancer

Lung cancer continues to be a major health problem with a very high
'/>"/>

SOURCE IDM Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... Harvard medical expert internationally recognized as a leading ... decision last month to suspend Doug Barron for ... having the medical condition hypogonadism and ... unfair and discriminatory." ,, Hypogonadism is ... often referred to informally as Low T ...
(Date:12/15/2009)... -- Fenwal Inc., a global medical technology company ... availability, announced today that the U.S. Food and ... InterSol ® platelet additive solution. Fenwal ... specialized product used in combination with human plasma ... used to prevent or treat bleeding. ,, InterSol ...
(Date:12/15/2009)... -- Reportlinker.com announces that a new market ... ,, Boehringer Ingelheim GmbH: PharmaVitae Profile ... Introduction ,, This analysis examines the ... in the Rx pharmaceutical sector. The profile ... and assessment of financial performance, with 1-6 ...
Breaking Medicine Technology:Harvard Medical Expert Criticizes PGA Tour, Calls Decision to Suspend Doug Barron for Doping 'Unreasonable, Unfair and Discriminatory' 2Harvard Medical Expert Criticizes PGA Tour, Calls Decision to Suspend Doug Barron for Doping 'Unreasonable, Unfair and Discriminatory' 3Harvard Medical Expert Criticizes PGA Tour, Calls Decision to Suspend Doug Barron for Doping 'Unreasonable, Unfair and Discriminatory' 4Fenwal Receives FDA Approval for New Solution Used to Store Donated Blood Platelets 2Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 2Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 3Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 4Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 5Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 6Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 7Heart Attacks Less Often Fatal Today 49550 1Heart Attacks Less Often Fatal Today 49550 2Heart Attacks Less Often Fatal Today 49550 3EUROPACE raises remote monitoring profile 49546 1EUROPACE raises remote monitoring profile 49546 2EUROPACE raises remote monitoring profile 49546 3Governor Rendell Discusses Impact of Budget on Services for Families of Children With Autism 49543 1Governor Rendell Discusses Impact of Budget on Services for Families of Children With Autism 49543 2
... 28 Aida,Pharmaceuticals, Inc. (OTC Bulletin Board: AIDA) ... II field testing of its,anti-cancer drug, Rh-Apo2L. The ... intended to be a new drug therapy using ... is designed as a highly-targeted,therapy with direct function ...
... Initiate Phase III Program in First Half of ... Inc. (Nasdaq: IDEV ) today announced positive ... patients with acromegaly, a,disorder characterized by excessive blood ... factor 1 (IGF-1). The implant utilizes the Company,s,patented ...
Other Medicine Technology:Aida Announces Completion of Anti-Cancer Drug Phase Two Testing 2Indevus Pharmaceuticals Reports Positive Results of Phase II Octreotide Implant Trial 2Indevus Pharmaceuticals Reports Positive Results of Phase II Octreotide Implant Trial 3Indevus Pharmaceuticals Reports Positive Results of Phase II Octreotide Implant Trial 4Indevus Pharmaceuticals Reports Positive Results of Phase II Octreotide Implant Trial 5
(Date:12/15/2009)... Dec. 15 The failure of the ... to cut costs, much less the more effective ... the latest example of how big industry controls ... "The proposed drug amendment by Senator Dorgan (D-ND) ... Obama,s campaign pledge to allow Medicare to directly ...
(Date:12/15/2009)... -- Palo Alto Networks(TM), the network security company, ... PA-4000 Series next-generation firewalls for accurate threat prevention ... and control over applications such as peer-to-peer file ... university with eight facilities on five campuses. The ... number of academic schools and institutions throughout Japan. ...
(Date:12/15/2009)... couples of reproductive age were evaluated, Italian study found ... of children born with cystic fibrosis decreases when screening ... increases, a new study finds. , CF neonatal screening ... for many years. Since the 1990s, the area has ... infants born with CF. , Two different CF carrier ...
(Date:12/15/2009)... not delivered ,, WASHINGTON, Dec. 15 /PRNewswire-USNewswire/ ... ensure that healthcare reform does not override the ... companies in 37 states. ,, Prostate cancer screening ... population and individuals who are identifiable as high ... have a family history of prostate cancer. The ...
(Date:12/15/2009)... 15 Patient advocate ... Members of Congress that, "it doesn,t matter whether there,s ... - without a public option - give government authority ... also fund a new social agenda by shifting billions ... groups, newly arriving immigrants, and local politicians." ...
Breaking Medicine News(10 mins):Health News:Failure of Drug Importation Amendment in U.S. Senate is Latest Show of Industry's Controlling Hand in Health Reform Debate, According to Consumer Watchdog 2Health News:Failure of Drug Importation Amendment in U.S. Senate is Latest Show of Industry's Controlling Hand in Health Reform Debate, According to Consumer Watchdog 3Health News:Palo Alto Networks Next-Generation Firewalls Deliver High-Performance Network Protection for Shinshu University 2Health News:Palo Alto Networks Next-Generation Firewalls Deliver High-Performance Network Protection for Shinshu University 3Health News:Wider Adult Screening May Mean Fewer Children With Cystic Fibrosis 2Health News:Men's Health Network Calls on Congress to Complete President Obama's Promise on Health Care Reform 2
... ALBUQUERQUE, N.M., Sept. 22 Biomoda, Inc.,(OTC Bulletin ... diagnostics company, expanded its intellectual property portfolio,with approval ... its Trademarks,CyDx(R) and CyPath(R)., "We are pleased ... for,our product portfolio," said John Cousins, Biomoda president. ...
... A study appearing in the Sept. 18 issue of ... among individuals with no colorectal neoplasia (abnormal growths) on initial ... low. The data provides support for rescreening at an interval ... , "This research is very significant as it is the ...
... radiosurgery (SRS) and whole brain radiation therapy (WBRT) for ... twice the risk of developing learning and memory problems ... research from The University of Texas M. D. Anderson ... randomized trial were presented at today,s 50th annual meeting ...
... Sept. 22 Stern + Associates (S+A), the,rapidly ... in central New Jersey with offices in Cambridge,Mass., ... roster: Biotest,Diagnostics Corporation and the Pain Control product ... addition, S+A expanded its public relations,programming for Bracco ...
... Johnson & Johnson, Ernst & Young, and,Kaplan Eduneering ... AdvaMed 2008,s list of,sponsors includes industry leaders, consulting ... the Ontario Ministry of Economic,Development & Trade (MEDT) ... number of sponsors increased this year by 52% ...
... with Social Security Disability Insurance as population ages; though disability ... , ... Belleville, Ill.(Vocus) September 22, ... retirement age, an echoing wave of the working population is ...
Other Medicine News:Health News:U.S. Patent Office Grants Biomoda Registration for Trademarks 2Health News:Risk of colorectal cancer extremely low 5 years after a normal colonoscopy screening 2Health News:Whole brain radiation increases risk of learning and memory problems in cancer patients 2Health News:Whole brain radiation increases risk of learning and memory problems in cancer patients 3Health News:Stern + Associates Signs New Clients to Health Care Practice 2Health News:AdvaMed 2008 Sponsor Participation Increases by 52% 2Health News:AdvaMed 2008 Sponsor Participation Increases by 52% 3Health News:AdvaMed 2008 Sponsor Participation Increases by 52% 4Health News:Baby Boomers' Aging Wave Affects Social Security Disability Program 2Health News:Baby Boomers' Aging Wave Affects Social Security Disability Program 3Health News:Baby Boomers' Aging Wave Affects Social Security Disability Program 4Health News:Baby Boomers' Aging Wave Affects Social Security Disability Program 5
The HearTwave system is the original stand-alone Microvolt T-Wave Alternans (MTWA) testing platform....
... trabeculum provides the highest magnification of ANY gonioscopy ... treating the trabecular meshwork. One 62° mirror ... angle while the central portion of the lens ... for signs of glaucoma and other central retinal ...
The Mid Field 30° lens has a bi-concave design to provide a wider field of view with a 30 degree offset image....
... AFX Lens is a direct ... in an air-filled eye. In ... a primary air-fluid exchange vitrectomy ... sutureless design make it well ...
Medicine Products: